Revolution Medicines Enters the Market With a Bang
Revolution Medicines entered the market with a bang on Thursday. Although the company only priced shares are $17 apiece, the stock actually entered the market closer to $28.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 71
Is CVS Back on Track With Q4 Results?
CVS reported better than expected quarterly results before the markets opened on Wednesday, due in part to its acquisition of Aetna.
Big Pharma Sees a Rising Tide in Short Interest
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Biotech Short Sellers Focus on a Couple Favorites
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Is CVS Set to Wow Investors With Q4 Earnings Wednesday Morning?
CVS Health has faced strong headwinds since last year’s acquisition of health insurer Aetna, but its upcoming earnings report could prove to be a turning point.
5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and income investors.
Moderna Commits to $500 Million Capital Raise, With More Possible
Moderna Inc. (NASDAQ: MRNA) had been the biggest biotech initial public offering ever. The company was quite unlucky in the timing for its IPO, but it managed to get back into favor with investors.…
What the World Health Organization Still Hasn’t Done About Coronavirus
The WHO is convening a meeting Tuesday in Geneva to give researchers and medical practitioners a chance to share information about the coronavirus outbreak. That will help battle the disease, but could more have…
When Will Amarin Stock Sell-Off Be Over?
Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company looks well-poised to boost sales in 2020 and going forward.
Why This Acquisition Could Be Huge for Collegium Pharma
Collegium Pharma shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.
AbbVie Wows Again With Q4 Results
AbbVie released better than expected fourth-quarter financial results before the markets opened on Friday.
PPD Proves Optimistic in IPO Debut
PPD made an exciting entrance to the market Thursday, pricing its shares at the high end of the expected price range.
Why This First of Its Kind Anaphylaxis Treatment Could Be Huge
Aquestive Therapeutics shares jumped on Thursday after the firm announced that it had a constructive face-to-face meeting with the FDA concerning its “first of its kind” treatment of anaphylaxis.
Merck’s Spin-Off May Create Operational Risks for the Year Ahead
Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin out part of its operations. Executing this effort may create some operational uncertainty inside…
Why This FDA Approval Is a Big Win for Vivus
Vivus shares jumped on Wednesday after the company announced a crucial FDA for its supplemental New Drug Application for an improved formulation of Pancreaze.